You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

VEGFR Inhibitor

Showing 1 - 25 of 7,777
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sarcoma Trial in Shanghai (Apatinib monotherapy)

Recruiting
  • Sarcoma
  • Apatinib monotherapy
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiao Tong University School of Medicine
May 18, 2022

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Camrelizumab (anti-PD-1 inhibitor)
  • Apatinib (anti-VEGFR inhibitor)
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Hand-Foot Skin Reaction (HFSR) Trial in United States (OQL011, Vehicle Ointment)

Recruiting
  • Hand-Foot Skin Reaction (HFSR)
  • Whittier, California
  • +32 more
Jan 16, 2023

Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or

Recruiting
  • Triple-negative Breast Cancer
  • Pyrotinib with Capecitabine
  • +6 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2022

Refractory Soft Tissue Sarcomas Trial run by the NCI (Cabozantinib)

Active, not recruiting
Has Results
  • Refractory Soft Tissue Sarcomas
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 5, 2022

Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory

Recruiting
  • Advanced Malignant Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Metastatic Colorectal Cancer, mCRC Trial in Guangzhou (Tislelizumab & Fruquintinib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • mCRC
  • Tislelizumab & Fruquintinib
  • Guangzhou, Guangdong, China
  • +1 more
Jan 25, 2023

Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

Completed
  • Metastatic Breast Cancer
  • +2 more
  • Control group
  • Case group
  • (no location specified)
Jun 16, 2022

Sarcoma, Stomach Tumors, Tumors Trial run by the NCI (Pazopanib, ARQ 197)

Completed
  • Sarcoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jun 23, 2021

Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor Trial in Shanghai (drug, procedure, radiation)

Active, not recruiting
  • Oral Cancer
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital
Jul 23, 2021

Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France

Not yet recruiting
  • Metastatic Renal Cell Carcinoma
  • Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
  • Combination PD-1/PD-L1 ICI + VEGFR-TKI
  • Treatment pause
  • Bayonne, France
  • +24 more
Aug 10, 2022

Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Brisbane (D-4517.2)

Completed
  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Brisbane, Queensland, Australia
    Nucleus Network (Brisbane)
Sep 19, 2022

Adenocarcinoma, Pancreatic Tumors Trial in Saint Louis, Nashville (X-82, Everolimus)

Terminated
Has Results
  • Adenocarcinoma
  • Pancreatic Neoplasms
  • Saint Louis, Missouri
  • +1 more
Jun 15, 2021

Breast Cancer, Triple-Negative Breast Cancer Trial in Guangzhou, Nanjing, Shanghai (Anti-PD-1 mAb, VEGFR2 Tyrosine Kinase

Recruiting
  • Breast Cancer
  • Triple-Negative Breast Cancer
  • Anti-PD-1 monoclonal antibody
  • VEGFR2 Tyrosine Kinase Inhibitor
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2022

Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Camrelizumab, Apatinib Mesylate)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Ton
Jan 31, 2021

Thymic Carcinoma, NSCLC, Refractory Thoracic Tumors Trial in United States (VEGFR/PDGFR Dual Kinase Inhibitor X-82, Nivolumab)

Active, not recruiting
  • Thymic Carcinoma
  • +3 more
  • VEGFR/PDGFR Dual Kinase Inhibitor X-82
  • Nivolumab
  • Palo Alto, California
  • +6 more
Sep 21, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 7, 2023

Adenoid Cystic Carcinoma of the Head and Neck Trial in Shanghai (All-trans Retinoic Acid, VEGFR inhibitor, Chemotherapy)

Recruiting
  • Adenoid Cystic Carcinoma of the Head and Neck
  • All-trans Retinoic Acid
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital
Jan 31, 2021

Hand-Foot Skin Reaction (HFSR) Trial in Hangzhou (Nicotinic acid +Routine care, Routine care)

Unknown status
  • Hand-Foot Skin Reaction (HFSR)
  • Nicotinic acid +Routine care
  • Routine care
  • Hangzhou, Zhejiang, China
    First People's Hospital of Hangzhou
Mar 31, 2020

Cancer, Non Small Cell Lung Cancer Trial in United Kingdom (Vandetanib, Selumetinib)

Completed
Has Results
  • Cancer
  • Non Small Cell Lung Cancer
  • Vandetanib, Selumetinib
  • Headington, Oxford, United Kingdom
  • +3 more
Sep 9, 2021

Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in San Antonio (D-4517.2)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Los Angeles, California
  • +11 more
Jan 11, 2023

Advanced Renal Cell Carcinoma Trial in Japan (Cabozantinib)

Completed
Has Results
  • Advanced Renal Cell Carcinoma
  • Nagoya, Aichi, Japan
  • +18 more
Aug 22, 2021

Advanced Malignant Tumor, BRAF Gene Mutation, Metastatic Malignant Tumor Trial in Houston (Crizotinib, Laboratory Biomarker

Completed
  • Advanced Malignant Neoplasm
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2021

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2023

Colorectal Cancer, Colorectal Adenocarcinoma Trial in Houston (Brivanib, Irinotecan)

Terminated
Has Results
  • Colorectal Cancer
  • Colorectal Adenocarcinoma
  • Houston, Texas
    UT MD Anderson Cancer Center
Sep 1, 2020